Alvotech (NASDAQ:ALVO) achieved a significant milestone in the competitive biologics market on Monday, announcing the European debut of Gobivaz, the first biosimilar to the blockbuster inflammatory drug Simponi to reach the market anywhere in the world.
The rollout, conducted in partnership with Advanz Pharma, marks a critical expansion of Alvotech’s portfolio as it seeks to capture market share from established immunology treatments.
The commercial launch of Gobivaz, a biosimilar version of golimumab, begins today across Europe and the United Kingdom.
In the British market, the drug’s entry is bolstered by an NHS England tender award, which provides a structured procurement framework to accelerate patient access.
For the remainder of the European Economic Area, Alvotech indicated that availability will follow the completion of individual national pricing and reimbursement procedures.
The approval and subsequent launch of Gobivaz were supported by a comprehensive data package including analytical, pre-clinical, and clinical studies demonstrating that the biosimilar is highly similar to the reference product.
To ensure seamless transition for clinicians and patients, Alvotech is offering the treatment in the same dosages and presentations as the original Simponi.
The medicine is produced at the company’s vertically integrated manufacturing hub in Iceland, a facility designed to provide a resilient supply chain for global markets.
For Alvotech and its exclusive European commercialization partner, Advanz Pharma, the launch represents a first-mover advantage in a high-value therapeutic category.
As healthcare systems across Europe face mounting budget pressures, the introduction of a lower-cost golimumab alternative is expected to drive significant savings.